About Jasper Therapeutics
Jasper Therapeutics is a Healthcare company based in Redwood City (United States) founded in 1999 by Judith Shizuru and Susan Prohaska. Jasper Therapeutics has raised $216.1 million across 4 funding rounds from investors including Roche, ARE and Citadel. Its chief executive, as recorded, is Ronald Martell. Its focus areas include Life Sciences, Gene Therapy, Diversified and Rare Diseases. Its competitors include BridgeBio, Moderna and Forge Biologics; 3 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells. It offers Briquilimab a targeted anti c-Kit monoclonal antibody to deplete mast cells and diseased stem cells for chronic urticaria and lower to intermediate risk myelodysplastic syndromes.
- Headquarters Redwood City, United States
- Founders Judith Shizuru, Susan Prohaska
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website jaspertx.com
- Social LinkedIn X
- Total Equity Funding$216.1M (USD)
in 4 rounds
- Latest Funding Round$132M (USD), Series B
Jul 2026
- InvestorsRoche
& 4 more
Funding Insights of Jasper Therapeutics
Jasper Therapeutics has successfully raised a total of $216.1M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $132 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $216.1M
- Total Rounds 4
- Last Round Series B — $132M
- First Round $35M
(Dec 2019)
- Investors Count 5
All 4 funding rounds of Jasper Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $132M | Series B | – | – | – |
| Jan 2020 | $14.1M | Series A | – | Roche | – |
| Dec 2019 | $35M | Series A | – | – | |
| Dec 2019 | $35M | Series A | – | Qiming, Abingworth |
5 investors in total: 5 institutional.
Investors in Jasper Therapeutics
Jasper Therapeutics has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, ARE and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare companies are funded by Qiming, a venture capital firm. | qimingvcusa.com | Cambridge, United States | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States |
Investor details for Jasper Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Jasper Therapeutics
4 people are tracked at Jasper Therapeutics (4 in leadership).
| Name | Role | Group |
|---|---|---|
Judith Shizuru | Co-Founder | Leadership |
Susan Prohaska | Co-Founder | Leadership |
Ronald Martell | CEO | Leadership |
Bill Lis | CEO | Leadership |
Complete people profiles for Jasper Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Jasper Therapeutics
3 dated milestones of Jasper Therapeutics across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Jasper Therapeutics is founded.
- Funding First funding round of $35.0M.
- Funding Latest funding round, Series B, of $132.0M.
Competitors of Jasper Therapeutics
Jasper Therapeutics has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Moderna and Forge Biologics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. |
Detailed competitors of Jasper Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Jasper Therapeutics
The website of Jasper Therapeutics (jaspertx.com) receives about 5.7K visits a month.
- Monthly visits5.7K
▲ 8.1% vs previous month
Top companies in Cell Therapy
3 companies that operate in the same segment as Jasper Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Jasper Therapeutics
Complete news archive for Jasper Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Jasper Therapeutics
Jasper Therapeutics was founded in 1999 and raised its 1st funding round 20 years after it was founded.
Jasper Therapeutics is headquartered in Redwood City, United States. It is registered at Redwood City, California, United States.
Ronald Martell is the CEO of Jasper Therapeutics, as recorded in our data.
Jasper Therapeutics is a funded company, having raised a total of $216.1M across 4 funding rounds to date. The company's 1st funding round was a Series A of $35M, raised on Dec 2019.
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells. It offers Briquilimab a targeted anti c-Kit monoclonal antibody to deplete mast cells and diseased stem cells for chronic urticaria and lower to intermediate risk myelodysplastic syndromes.
Jasper Therapeutics's top competitors include Moderna, BridgeBio and Forge Biologics.
Jasper Therapeutics has 5 investors. Key investors include Roche, ARE, Citadel, Abingworth, and Qiming.